| Objective To assess the efficacy and safety of Irbesartan Treatment in Patients with Nephropathy Due to Type 2 Diabetes.Methods We searched PubMed,the Cochrane Library,EMbase,Medline,OVID,CBM,CNKI,VIP,Wanfang Data. Randomized controlled trials (RCT) of clinical therapeutic studies on Irbesartan Treatment in Patients with Nephropathy Due to Type 2 Diabetes were included. The quality of included studies was evaluated on the basis of the inclusion criteria and the exclusion criteria. Meta-analysis was performed according to the data and its results were assessed by sensitivity analysis and bias analysis with funnel plots.Result Ten trials involving 898 participants with Nephropathy Due to Type 2 Diabetes were included. There were 447 participants in treatment group and 451 participants in control group. Meta-analysis indicated that Irbesartan was more effective than Placebo in improving Urinary albumin excretion rate, Systolic blood pressure, diastolic blood pressure. The WMD (95 % CI) were [WMD=11.3 ,95%CI(7.46,15.15)],[WMD=6.45,95%CI(4.82,8.08)],[WMD=8.38,95%CI (7.08,9.67)]respectively. But it was not statistically significant in improving HbA1C compared with Placebo(P>0.1),WMD(95%CI)[WMD=-0.06,95%CI (-0.18,0.06)]. Slight adverse effects were reported in 7 studies. It suggested that Irbesartan was safe.Conclusion Irbesartan is effective,safe and well tolerated in the management of patients with Nephropathy Due to Type 2 Diabetes. However,the evidence is not strong enough due to the low quality trials and inadequate samples.Further good quality,large-sample and multi-center studies are needed to assess the efficacy and safety of Irbesartan. In addition,it is recommended in future clinical trials we should pay more attention to negative results were reported. |
PDF Full Text Request